Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective
Christopher McCabe(University of Leeds), H. Zwierzina(Innsbruck Medical University), V. Nüßler(Ludwig-Maximilians-Universität München), Nils Wilking(Sophiahemmet Hospital), Nicholas Bosanquet(Imperial College London), Harald Enzmann(Federal Institute for Drugs and Medical Devices), Mary Ellis, Lothar Bergmann(Universität Ulm), Bertil Jönsson(Medical Products Agency), C. Teale(AstraZeneca (United Kingdom)), R. de Wilde, B Paschen(Merck KGaA, Darmstadt (Germany)), Karl‐Josef Kallen(CureVac (Germany)), Don Newling(AstraZeneca (United Kingdom)), Mia von Euler(University Hospital of North Norway)
Cited by 67
Related Papers
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
|Journal of Clinical Oncology|2000|996
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
|Journal of Clinical Oncology|2000|840
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803